Miromatrix Medical Inc.

NasdaqCM:MIRO Stock Report

Market Cap: US$93.0m

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Miromatrix Medical Dividends and Buybacks

Dividend criteria checks 0/6

Miromatrix Medical does not have a record of paying a dividend.

Key information

n/a

Dividend yield

-9.7%

Buyback Yield

Total Shareholder Yield-9.7%
Future Dividend Yieldn/a
Dividend Growthn/a
Next dividend pay daten/a
Ex dividend daten/a
Dividend per sharen/a
Payout ration/a

Recent dividend and buyback updates

No updates

Recent updates

Analysis Article Oct 28

Miromatrix Medical (NASDAQ:MIRO) Will Have To Spend Its Cash Wisely

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analysis Article Jul 01

We're A Little Worried About Miromatrix Medical's (NASDAQ:MIRO) Cash Burn Rate

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
Analysis Article Mar 08

Here's Why We're A Bit Worried About Miromatrix Medical's (NASDAQ:MIRO) Cash Burn Situation

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
Analysis Article Sep 30

Here's Why We're Watching Miromatrix Medical's (NASDAQ:MIRO) Cash Burn Situation

We can readily understand why investors are attracted to unprofitable companies. For example, although...
Seeking Alpha Aug 25

Miromatrix gets US patent for recellularizing technology for use in organ transplant

Miromatrix Medical (NASDAQ:MIRO) said it has received a new patent from the U.S. Patent and Trademark Office for its perfusion decellularization and recellularization technology. The patent number 11,414,644 titled 'Methods of Recellularizing a Tissue or Organ for Improved Transplantability' covers the revascularization of decellularized organs and tissues which include all types of organs including liver, lung, kidney, and heart. The new patent expands the company's patent portfolio covering the bioengineering of transplantable organs, Miromatrix said in an Aug. 25 press release.
Seeking Alpha Aug 15

Miromatrix Medical GAAP EPS of -$0.40 misses by $0.07, revenue of $3.95M

Miromatrix Medical press release (NASDAQ:MIRO): Q2 GAAP EPS of -$0.40 misses by $0.07. Revenue of $3.95M.

Stability and Growth of Payments

Fetching dividends data

Stable Dividend: Insufficient data to determine if MIRO's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if MIRO's dividend payments have been increasing.


Dividend Yield vs Market

Miromatrix Medical Dividend Yield vs Market
How does MIRO dividend yield compare to the market?
SegmentDividend Yield
Company (MIRO)n/a
Market Bottom 25% (US)1.4%
Market Top 25% (US)4.2%
Industry Average (Life Sciences)0.6%
Analyst forecast (MIRO) (up to 3 years)n/a

Notable Dividend: Unable to evaluate MIRO's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate MIRO's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate MIRO's payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as MIRO has not reported any payouts.


Discover strong dividend paying companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2023/12/14 00:07
End of Day Share Price 2023/12/12 00:00
Earnings2023/09/30
Annual Earnings2022/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Miromatrix Medical Inc. is covered by 2 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Alexander NowakCraig-Hallum Capital Group LLC
Matthew O'BrienPiper Sandler Companies